P-Glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies

Cancer Research

Volumn 59, Issue 16, 1999, Pages 3944-3948

  Wandel, Christoph ^a   Richard B, Kim ^a   Kajiji, Shama ^c   Guengerich, F Peter ^a   Wilkinson, Grant R ^a   Wood, Alastair J J ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLYCOPROTEIN P; NIFEDIPINE;

ARTICLE; CELL STRAIN CACO 2; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; EPITHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TUMOR GROWTH;

ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DIGOXIN; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; SUBSTRATE SPECIFICITY;

EID: 0345411341     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. Cellular localization of the multidrug-resistaitce gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738, 1987.
2. Sugawara, I., Kataoka, I., Morishita, Y., Hamada, H., Tsuruo, T., Hoyama, S., and Mon, S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res., 48: 1926-1929, 1988.
3. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem., 37: 159-164, 1989.
4. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., and Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA, 86: 695-698, 1989.
5. Leveque, D., and Jehl, F. P-glycoprotein and pharmacokinetics. Anticancer Res., 15: 231-336, 1995.
6. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., and Borst, P. Absence of the mdr 1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Invest., 96: 1698-1705, 1995.
7. Relling, M. V. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit., 18: 350-356, 1996.
8. Gottesman, M. M., Pastan, I., and Ambudkar, S. V. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev., 6: 610-617, 1996.
9. Ling, V. Multidrug resistance. Molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol., 40 (Suppl.): S3-S8, 1997.
10. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41: 1967-1972, 1981.
11. Ford, J. M., Bruggemann, E. P., Pastan, I., Gottesman, M. M., and Hait, W. N. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res., 50: 1748-1756, 1990.
12. Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollimger, P., and Loor, F. In vitro circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51: 4226-4233, 1991.
13. Raderer, M., and Scheithauer, W. Clinical trials of agents that reverse multidrug resistance. Cancer (Phila.), 72: 3553-3563, 1993.
14. Ford, J. M., and Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer: effects of chemosensitizers in human trials. Pharmacol. Rev., 42:181-183, 1990.
15. Bates, S. E., Wilson, W. H., Fojo, A. T., Alvarez, M., Zhan, Z., Regis, J., Robey, R., Hose, C., Monks, A., Kang, Y. K., and Chabner, B. Clinical reversal of multidrug resistance. Stem Cells, 14: 56-63, 1996.
16. Lum, B. L., Kaubisch, S., Yahanda, A. M., Adler, K. M., Jew, L., Ehsan, M. N., Brophy, N. A., Halsey, J., Gosland, M. P., and Sikic, B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosponne in a Phase I trial to modulate multidrug resistance. J. Clin. Oncol., 10: 1635-1642, 1992.
17. Tolcher, A. W., Cowan, K. H., Solomon, D., Ognibene, F., Goldspiel, B., Chang, R., Noone, M. H., Denicoff, A. M., Barnes, C. S., Gossard, M. R., Fetsch, P. A., Berg, S. L., Balis, F. M., Venzon, D. J., and O'Shaughnessy, J. A. Phase I crossover study of paclitaxel with R-verapamil in patients with metastatic breast cancer. J. Clin. Oncol., 14: 1173-1184, 1996.
18. Sonneveld, P., Marie, J. P., Huisman, C., Vekhoff, A., Schoester, M., Faussat, A. M., Vankapel, J., Groenewegen, A., Charnick, S., Zizzoun, R., and Lowenberg, B. Reversal of multidrug-resistance by SDZ PSC-833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma-a Phase I study. Leukemia (Baltimore), 10: 1741-1750, 1996.
19. Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H., and Bleehen, N. M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug-resistance in patients with cancer. J. Clin. Oncol., 14: 610-618, 1996.
20. Wacher, V. J., Wu, C. Y., and Benet, L. L. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13: 129-134, 1995.
21. Kim, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., Wood, A. J. J., and Wilkinson, G. R. Interrelationship between inhibitors and substrates of human CYP 3A and P-glycoprotein. Pharmacol. Res., 16: 408-414, 1999.
22. Kivistoe, K. T., Kroemer, H. K., and Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol., 40: 523-530, 1995.
23. Harris, J. W., Rahman, A., Kim, B-R., Guengerich, F. P., and Collins, J. M. Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and of an unknown P450 enzyme. Cancer Res., 54: 4026-4035, 1994.
24. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., and Berthou, F. Identification of the cytochrome P450IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41: 1911-1919, 1991.
25. Lau, D. H., Duran, G. E., Lewis, A. D., and Sikic, B. I. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br. J. Cancer, 70: 79-84, 1994.
26. Ren, S., Yang, J-S., Kalhorn, T. F., and Slattery, J. T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res., 57: 4229-4235, 1997.
27. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J., Roden, D. M., and Wilkinson, G. R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 101: 289-294, 1998.
28. Ito, S., Koren, G., Harper, P. A., and Silverman, M. Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1). Can. J. Physiol. Pharmacol., 71: 40-47, 1993.
29. Guengerich, F. P. Analysis and characterization of enzymes. In: A. W. Hayes (ed.), Principles and Methods of Toxicology, Ed. 3, pp. 1259-1313. New York: Raven Press, 1994.
30. Omura, T., and Sato, R. The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem., 239: 2370-2378, 1964.
31. Guengerich, F. P., Martin, M. V., Beune, P. H., Kremers, P., Wolff, T., and Waxman, D. J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 261: 5051-5060, 1988.
32. Segel, I. H. Enzyme Kinetics. New York: Wiley, 1975.